Can B Corp. FY22 Revenue Grows 45% To $6.7M, Here Are The Details
Can B Corp. FY22 Revenue Grows 45% To $6.7M, Here Are The Details
Can B Corp. (OTCQB:CANB) released its financial results for the twelve months ended December 31, 2022, revealing revenue increased 45% to $6.7 million, compared with $4.6 million in 2021.
Can B Corp. (OTCQB: CANB) 公佈了截至2022年12月31日的十二個月的財務業績，披露 收入增長了45％，達到670萬美元， 相比之下，2021年的這一數字爲460萬美元。
Financial Highlights for 2022
2022 年財務亮點
-
Gross profit decreased 13% to $2.6 million.
-
Gross margin decreased to 39.1%, compared to 65.0% in 2021.
-
Adjusted EBITDA loss decreased by 25% to $2.1 million.
-
Net loss was $14.9 million, or ($4.18) per share, an increase of $2.8 million, or 23%, compared with a net loss of $12.1 million, or a net loss of ($9.06) per share, for the twelve months ended December 31, 2021. On a per-share basis this loss is a 46% reduction over 2021.
-
Total assets at $15.6 million.
-
毛利下降了13％，至260萬美元。
-
毛利率下降至39.1％，而2021年爲65.0％。
-
調整後的息稅折舊攤銷前利潤虧損下降了25％，至210萬美元。
-
淨虧損爲1,490萬美元，合每股虧損4.18美元，增加了280萬美元，增幅23％，而截至2021年12月31日的十二個月淨虧損爲1,210萬美元，即每股淨虧損9.06美元。按每股計算，虧損比2021年減少了46％。
-
總資產爲1,560萬美元。
Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange
公司債務重組有望在國家證券交易所上市
Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024, to give the company an additional window to deploy the capital from the new raise. A key component of the restructuring was the sale of $5.7 million of accounts receivable from Can B's Duramed Inc. and Duramed MI, LLC divisions to fund payments on two promissory notes for $2.5 million and $1.5 million due to Can B Corp's largest institutional investor.
通過重組，Can B 籌集了155萬美元的新資金，並將先前到期的總額爲700萬美元的應付票據延長至2023年9月1日和2024年12月31日，爲公司提供了額外的窗口來部署新籌集的資金。重組的一個關鍵組成部分是出售Can B's的570萬美元應收賬款 Duramed Inc. 和 密歇根州杜拉梅， 有限責任公司 各部門將爲兩張期票的支付提供資金，分別爲250萬美元和150萬美元應歸於Can B Corp最大的機構投資者。
Marco Alfonsi, Can B's CEO, stated, "2022 was a transition year for us, for as we increased revenue as expected and achieved record annual revenue of $6.7 million, we had to deal with consolidating business and integrating our acquisitions. We are pleased with the position of our business heading into the remainder of 2023."
馬可·阿方西，Can B 首席執行官表示：“2022 年對我們來說是過渡年，因爲隨着我們按預期增加收入並實現創紀錄的670萬美元年收入，我們不得不處理整合業務和整合收購的問題。我們對2023年剩餘時間的業務狀況感到滿意。”
Alfonsi concluded, "While we generated an all-time high in annual revenue, we were able to also reduce our cash burn as demonstrated by the 25% decrease in adjusted EBITDA loss to $2.1 million. Our team made great strides over the past several months integrating and ramping up the various operations. We strategically acquired additional processing equipment to complete our vertical hemp processing capabilities from biomass to crude to distillate to isolate to isomers- all now located in our Colorado operation. We are executing on major strategic agreements, such as Pure Health Products' deal with Brooke Burke Superfood, and are very excited about the demand and results thus far. As we look forward in 2023, we are enthusiastic regarding the growth opportunities and prospects for our business and are in position for an uplisting to a national securities exchange."
阿方西總結說：“儘管我們的年收入創下了歷史新高，但我們也能夠減少現金消耗，調整後的息稅折舊攤銷前利潤虧損減少了25％，至210萬美元，就證明了這一點。在過去的幾個月中，我們的團隊在整合和加強各種業務方面取得了長足的進步。我們戰略性地購買了額外的加工設備，以完善我們的垂直大麻加工能力，從生物質到原油再到餾出物再到分離物再到異構體，所有這些都位於我們的科羅拉多州工廠中。我們正在執行重大戰略協議，例如 純健康產品'處理 布魯克·伯克超級食品，並對迄今爲止的需求和結果感到非常興奮。展望2023年，我們對業務的增長機會和前景充滿熱情，並準備在國家證券交易所上市。”
Photo by Esteban López on Unsplash
埃斯特萬·洛佩茲在 Unsplash 上拍的照片
Related News
相關新聞
Can B Corp. Stock Takes A 51% Plunge On Record Quarterly Revenue
Can B Corp. 股價在創紀錄的季度收入基礎上暴跌了51％
譯文內容由第三人軟體翻譯。